Drug Approval | May 01, 2026
Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Health innovations are viewed more positively than food and agricultural technologies
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
Subscribe To Our Newsletter & Stay Updated
